{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:17:06Z","timestamp":1778897826458,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012028","name":"Trombosestichting Nederland","doi-asserted-by":"publisher","award":["grant2018-01"],"award-info":[{"award-number":["grant2018-01"]}],"id":[{"id":"10.13039\/501100012028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012028","name":"Trombosestichting Nederland","doi-asserted-by":"publisher","award":["2018-01"],"award-info":[{"award-number":["2018-01"]}],"id":[{"id":"10.13039\/501100012028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024872","name":"Toegepaste en Technische Wetenschappen, NWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009425","name":"Landsteiner Foundation for Blood Transfusion Research","doi-asserted-by":"publisher","award":["1504"],"award-info":[{"award-number":["1504"]}],"id":[{"id":"10.13039\/100009425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009425","name":"Landsteiner Foundation for Blood Transfusion Research","doi-asserted-by":"publisher","award":["grant1504"],"award-info":[{"award-number":["grant1504"]}],"id":[{"id":"10.13039\/100009425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2026.103366","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:00:34Z","timestamp":1769587234000},"page":"103366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allele-selective von Willebrand factor silencing"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-5759","authenticated-orcid":false,"given":"Jeroen","family":"Eikenboom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-3446","authenticated-orcid":false,"given":"Noa","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-7005","authenticated-orcid":false,"given":"Yvonne","family":"Jongejan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103366_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103366_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41572-024-00536-8","article-title":"von Willebrand disease","volume":"10","author":"Seidizadeh","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rpth.2026.103366_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103366_bib4","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","article-title":"von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam study","volume":"36","author":"Sonneveld","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2026.103366_bib5","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/STROKEAHA.110.586289","article-title":"High von Willebrand factor levels increase the risk of stroke: the Rotterdam study","volume":"41","author":"Wieberdink","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2026.103366_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2020.10.037","article-title":"ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis","volume":"197","author":"Pagliari","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103366_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rpth.2026.103366_bib9","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1016\/j.jtha.2024.08.028","article-title":"Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study","volume":"22","author":"van Kwawegen","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib10","first-page":"588","article-title":"von Willebrand disease and angiodysplasia: a wider view of pathogenesis in pursuit of therapy","volume":"110","author":"Crossette-Thambiah","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.103366_bib11","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1111\/bcp.15221","article-title":"Antiplatelet therapy in cardiovascular disease: Current status and future directions","volume":"88","author":"Passacquale","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.103366_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103366_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.gene.2013.12.019","article-title":"Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies","volume":"538","author":"Deng","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.rpth.2026.103366_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103366_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.rpth.2026.103366_bib16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.103366_bib17","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1073\/pnas.1231012100","article-title":"Allele-specific silencing of dominant disease genes","volume":"100","author":"Miller","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.103366_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/sj.jid.5701060","article-title":"Single-nucleotide-specific siRNA targeting in a dominant-negative skin model","volume":"128","author":"Hickerson","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.rpth.2026.103366_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2026.103366_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.04.003","article-title":"Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita","volume":"51","author":"Leachman","year":"2008","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.rpth.2026.103366_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049757","article-title":"Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathy","volume":"7","author":"Loy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.103366_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.rpth.2026.103366_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/18796397241293955","article-title":"Huntington\u2019s disease clinical trials update: September 2024","volume":"13","author":"Farag","year":"2024","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.rpth.2026.103366_bib24","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2010-02-268920","article-title":"The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation","volume":"116","author":"Casari","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103366_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jth.15131","article-title":"In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A","volume":"19","author":"Campioni","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"de Jong","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103366_bib27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/jth.14140","article-title":"Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor","volume":"16","author":"de Jong","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr Biol"},{"key":"10.1016\/j.rpth.2026.103366_bib29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.rpth.2026.103366_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1160\/TH06-08-0460","article-title":"Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease","volume":"96","author":"Tjernberg","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib31","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/nprot.2012.093","article-title":"Establishment of outgrowth endothelial cells from peripheral blood","volume":"7","author":"Martin-Ramirez","year":"2012","journal-title":"Nat Protoc"},{"key":"10.1016\/j.rpth.2026.103366_bib32","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1111\/jth.14998","article-title":"Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease","volume":"18","author":"de Boer","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1055\/s-0040-1715442","article-title":"Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-interfering RNA","volume":"120","author":"de Jong","year":"2020","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2026.103366_bib34","article-title":"Allele specific knock-out of mutant Von Willebrand factor in heterozygous Von Willebrand disease type 2A patient-derived ECFCs [abstract OC 58.2]","volume":"8","author":"B\u00e4r","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib35","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1182\/bloodadvances.2023010643","article-title":"Small interfering RNA-mediated allele-selective silencing of von Willebrand factor in vitro and in vivo","volume":"7","author":"Jongejan","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103366_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2014.84","article-title":"In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight","volume":"9","author":"Dahlman","year":"2014","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.rpth.2026.103366_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.thromres.2024.03.002","article-title":"Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor","volume":"236","author":"Jongejan","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103366_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/srep26306","article-title":"A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation","volume":"6","author":"Adam","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2026.103366_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/bloodadvances.2024014601","article-title":"Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs","volume":"9","author":"Linthorst","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103366_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102699","article-title":"Silencing of the von Willebrand factor gene in proatherothrombotic APOE\u22173-Leiden.CETP transgenic mice","volume":"9","author":"Jongejan","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2026.103366_bib41","article-title":"VELORA Pioneer: first-in-human safety and PK\/PD study of HMB-002 in type 1 von Willebrand disease [abstract LB 01.4]","volume":"9","author":"Raheja","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2026.103366_bib42","article-title":"HMB-002: elevating von Willebrand Factor for prophylactic treatment of Von Willebrand Disease [abstract OC 08.4]","volume":"9","author":"H\u00e4ger","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2026.103366_bib43","article-title":"Favorable nonclinical safety profile of HMB-002 for prophylactic treatment of Von Willebrand disease [abstract OC 59.5]","volume":"9","author":"Rasmussen","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2026.103366_bib44","article-title":"Phenotype correction of von Willebrand disease by AAV vectors delivering only VWF propeptide [abstract OC 08.1]","volume":"9","author":"Zhang","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib45","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/jth.15804","article-title":"Contribution of ADAMTS13-independent VWF regulation in sickle cell disease","volume":"20","author":"Hunt","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207592119","article-title":"Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease","volume":"119","author":"Shi","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.103366_bib47","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/jth.15312","article-title":"Targeting von Willebrand factor in liver diseases: a novel therapeutic strategy?","volume":"19","author":"Groeneveld","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103366_bib48","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/jcm11071835","article-title":"ADAMTS13, VWF, and endotoxin are interrelated and associated with the severity of liver cirrhosis via hypercoagulability","volume":"11","author":"Takaya","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.103366_bib49","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/jth.14976","article-title":"Von Willebrand factor and cancer; metastasis and coagulopathies","volume":"18","author":"Patmore","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:55:09Z","timestamp":1778896509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037926000245"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103366","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allele-selective von Willebrand factor silencing","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103366"}}